Project Grant HT94252310263
Award Date
5/1/23
Completion Date
4/30/27
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02138, USA
Similar Awards
The Defense Health Agency awarded a $716,069 Project Grant to President And Fellows Of Harvard College, doing business as Harvard Medical School, to conduct research from September 1, 2023 through August 31, 2025. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative research and investigate medical solutions for the...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $676,000.00 in funding to President and Fellows of Harvard College, doing business as Harvard Medical School, to develop HUWE1 as a therapeutic target for treating mesothelioma. The award period runs from July 1, 2025 to June 30, 2027. As a renowned academic and research institution, Harvard Medical School will leverage its expertise in biomedical...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
This $676,147 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a research initiative led by Harvard University to develop data-driven biomarker-informed decision analytics to improve the efficacy and reduce the toxicity of immune checkpoint blockade therapy for melanoma patients. The 3-year project aims to leverage advanced analytics and biomarker data to optimize the use of this cutting-edge cancer...
This $1,186,517 Project Grant was awarded by the Defense Health Agency on August 1, 2023 to Harvard College President & Fellows Of Harvard T.H. Chan School Of Public Health under the Military Medical Research and Development (CFDA 12.420) program. The goal of the 3-year project is to REVEAL AND TARGET LIPIDOMIC VULNERABILITIES TO TREAT METASTATIC MELANOMA. Harvard T.H. Chan School of Public Health will conduct research to investigate new ways to treat this deadly form of skin cancer. No...
This federal Project Grant award of $539,904.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at the Harvard T.H. Chan School of Public Health to develop "Genomically Informed Morphological Stromal Signatures to Predict Lethal Prostate Cancer." The research project, with a performance period from June 2025 to June 2028, aims to leverage genomic and morphological data to identify novel biomarkers for...
This Project Grant award from the Defense Health Agency provides $377,681 to the University of Cambridge for research elucidating and targeting clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The award period runs from April 1, 2023 through March 31, 2026. The research funded under this award directly supports the Military Medical Research and Development program's goal of investigating medical solutions for the...
The University of Cambridge will receive $439,922 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from September 2022 through September 2025 to dissect ovarian cancer tumor-immune microenvironments through 3D in situ molecular profiling. The Military Medical Research and Development program aims to transform military and public health through innovative medical research...
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...